New therapeutic aspects of inflammatory cardiomyopathy

Current Pharmaceutical Design

Volumn 21, Issue 4, 2015, Pages 459-465

  Kuchynka, Petr ^a,b   Palecek, Tomas ^a,b   Nemecek, Eduard ^a   Fikrle, Michal ^a   Linhart, Ales ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Antimicrobial treatment; Endomyocardial biopsy; Immunosuppression; Inflammatory cardiomyopathy; Myocarditis

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE BIOPSY; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CARDIOMYOPATHY; MYOCARDITIS; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; VIRAL CLEARANCE; VIRUS LOAD; BIOPSY; CARDIOMYOPATHIES; ENDOCARDIUM; HEART FUNCTION TEST; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

BIOPSY; CARDIOMYOPATHIES; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; ENDOCARDIUM; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING;

EID: 84925854366     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282104141204142244     Document Type: Article

References (64)

1. [1] Kindermann I, Barth Ch, Mahfoud F, et al. Update on myocarditis. JACC 2012; 9: 779-92.
2. [2] Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29: 270-6.
3. [3] Kühl U, Schultheiss HP. Myocarditis. Dtsch Arzetebl Int 2012; 109: 361-8.
4. [4] Grumbach IM, Heim A, Pring-Akerblom P, et al. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol 1999; 54: 83-8.
5. [5] Pankuweit S, Hufnagel G, Eckhardt H, et al. Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation. Med Klin 1998; 93: 223-8.
6. [6] Breinholt JP, Moulik M, Dreyer WJ, et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant 2010; 29: 739-46.
7. [7] Iglezias SD, Benvenuti LA, Calabrese F, et al. Endomyocardial fibrosis: pathological and molecular findings of surgically resected ventricular endomyocardium. Virchows Arch 2008; 453: 233-41.
8. [8] Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2002; 39: 892-5.
9. [9] Lotze U, Egerer R, Glück B, et al. Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol 2010; 82: 1449-57.
10. [10] Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010; 362: 1248-9.
11. [11] Quiros FR, Moralko CA, Casas JP, et al. Charity: Chagas cardiomyopathy bisoprolol intervention study: a randomized double blind force titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy. Trials 2006; 7: 21.
12. [12] Palecek T, Kuchynka P, Hulinska D, et al. Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy. Med Microbiol Immunol 2010; 199: 139-43.
13. [13] Kubánek M, _ramko M, Berenová D, et al. Detection of Borrelia burgdorferi sensu lato in edomyocardial biopsy specimens in individuals with recent-onset dilated cardiomyopathy. Eur J Heart Fail 2012; 14: 588-96.
14. [14] Noutsias M, Pauschinger M, Poller WC, et al. Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit 2003; 3: 127-35.
15. [15] Poller W, Fechner H, Noutsias M, et al. The molecular basis of cardiotropic viral infections. Eur Heart J Supplements 2002; 4: I18-30.
16. [16] Hare JM, Colucci WS. Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 1995; 38: 155-66.
17. [17] Gupta S, Markham DW, Drazner MH,et al. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 2008; 5: 693-706.
18. [18] D’Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85: 499-504.
19. [19] Pankuweit S, Portig I, Lottspeich F, et al. Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. J Mol Cell Cardiol 1997; 29: 77-84.
20. [20] Caforio AL, Mahon NJ, Tona F, et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002; 4: 411-7.
21. [21] Lawson CM. Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis. Cell Mol Life Sci 2000; 57: 552-60.
22. [22] Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary instance in human diseases Cell Mol Life Sci 2000; 57: 542-51.
23. [23] Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360: 1526-38.
24. [24] Lauer B, Niederau C, Kühl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30: 1354-9.
25. [25] Mahfoud F, Gärtner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32: 897-903.
26. [26] Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005; 111: 887-93.
27. [27] Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18: 733-46.
28. [28] Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000; 36:227-32.
29. [29] Röttgen R, Christiani R, Freyhardt P, et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol 2011; 21: 1259-66.
30. [30] Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. JACC 2009; 53: 1475-87.
31. [31] Fowles RE, Mason JW. Endomyocardial biopsy. Ann Intern Med 1982; 97: 885-94.
32. [32] Aretz HT, Billingham ME, Edward WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1: 3-14.
33. [33] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
34. [34] Salvi A, Di Lenarda A, Dreas L, et al. Immunosuppressive treatment in myocarditis. Int J Cardiol 1989; 22: 329-38.
35. [35] Dec GW, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies-Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312: 885-90.
36. [36] Mason JW, O’Connell JB, Herskowitz A, et al. A clinical trial immunosuppresive therapy for myocarditis. N Engl J Med 1995; 333: 269-75.
37. [37] Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45.
38. [38] Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107: 857-63.
39. [39] Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virusnegative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30: 1995-2002.
40. [40] Maisch B, Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. Herz 2012; 37: 644-56.
41. Staudt A, Hummel A, Ruppert A, et al. Immunoadsorption in dilated cardiomyopathy:6-month results from a randomized study. Am Heart J 2006; 152:712.e1-712.e6.
42. [42] Felix SB, Staudt A, Dörffel WV, et al. Hemodynamic effects of imunoadsorption and subsequent imunoglobulin substitution in dilated cardiomyopathy. J Am Coll Cardiol 2000; 35: 1590-8.
43. [43] Staudt A, Schäper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by imunoadsorption therapy and subsequent imunoglobulin substitution. Circulation 2001; 103: 2681-6.
44. [44] Staudt A, Staudt Y, Hummel A, et al. Effects of immunoadsorption on the nt-BNP andnt-ANP plasma levels of patients suffering from dilated cardiomyopathy, Ther Apher Dial 2006; 10: 42-8.
45. [45] Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
46. [46] Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the paediatric population. Circulation 1994; 89: 252-7.
47. [47] McNamara DM, Rosenblum WD, Janosko K, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95: 2476-8.
48. [48] McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous. Immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-9.
49. [49] Dennert R, Velthuis S, Schalla S, et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 2010; 15: 193-201.
50. [50] Maisch B, Pankuweit S. Standard and etiology-directed evidencebased therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev 2013; 18: 761-95.
51. [51] Wang YX, da Cunha V, Vincelette J, et al. Antiviral and myocyte protective effects of murine interferon-beta and-{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol Heart Circ Physiol. 2007; 293: 69-76.
52. [52] Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-8.
53. [53] Schultheiss HP, Piper C, Sowade K, et al. The effect of subcutaneous treatment with interferon-beta-1b over 24 weeks on safety, virus elimination and clinical outcome in patients with chronic viral cardiomyopathy (abstr). Circulation 2008; 118: 3322.
54. [54] Steere AC. Lyme disease. N Engl J Med 2001; 345: 115-25.
55. [55] Koene R, Boulware DR, Kemperman M, et al. Acute Heart Failure from Lyme Carditis. Circ Heart Fail 2012; 5: e24-e26.
56. [56] Gasser R, Dusleag J, Reisinger E, et al. Reversal by ceftriaxone of dilated cardiomyopathy borrelia burgdorferi infection. Lancet 1992; 339: 1174-5.
57. [57] Krejci J, Poloczkova H, Hude P, et al. Impact of inflammatory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters. Cor et Vasa 2013; 55: e333-e340.
58. [58] Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616-25.
59. [59] Barbandi M, Cordero-Reyes A, Orrego CM, et al. A case series of reversible acute cardiomyopathy associated with H1N1 influenza infection. Methodist DeBakey Cardiovasc J 2012; 8: 42-5.
60. [60] Stack WA, Mulcahy HE, Fenelon L, et al. Cytomegalovirus myocarditis following liver transplantation. Postgrad Med J 1994; 70: 658-60.
61. [61] Lenzo JC, Shellam GR, Lawson CM. Ganciclovir and Cidofovir Treatment of cytomegalovirus-Induced Myocarditis in Mice. Antimicrob Agents Chemother 2001; 45: 1444-9.
62. [62] Weinkauf J, Walia R, Berry GJ, et al. Lymphocytic Myocarditis After Lung Transplantation. J Heart Lung Transplant 2005; 24: 1163-5.
63. [63] Kuchynka P, Palecek T, Hrbackova H, et al. Herpes simplex virusinduced cardiomyopathy successfully treated with acyclovir. Wien Klin Wochenschr 2010; 122: 592-5.
64. [64] Barbaro G. Heart and HAART: Two sides of the coin for HIVassociated cardiology issues. World J Cardiol 2010; 2: 53-7.